

Special Issue

Resistance and Tolerance of *Helicobacter pylori*

Message from the Guest Editors

Resistance to antibiotics is a global phenomenon generating huge costs and therapeutic difficulties. Therefore, monitoring of microbial resistance is one of the most important tasks of modern medicine. As a result of this, in 2017 the World Health Organization created a list of priority pathogens within which *Helicobacter pylori* was mentioned. The inclusion of this bacterium on the above list was associated with its ability to persistently colonize the host and induce a broad range of gastric diseases (including cancers), but was also related to the easiness of this pathogen to acquire resistance genes and become difficult to be treated. The assumption of this Special Issue is to highlight the postulates of the WHO and to draw the attention of both scientists and clinicians to the importance of understanding mechanisms of *H. pylori* resistance and tolerance as a key strategy aimed at maintaining a high degree of eradication of this pathogen. As part of the Special Issue, we encourage to submit original research papers, short communications, and reviews describing the molecular phenomena responsible for the development of *H. pylori* antibiotic resistance.

Guest Editors

Dr. Paweł Krzyżek
Dr. Rossella Grande
Dr. Valentina Puca

Deadline for manuscript submissions

closed (30 June 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/104382

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)